Novel therapeutic agents for osteosarcoma

Expert Rev Anticancer Ther. 2009 Apr;9(4):511-23. doi: 10.1586/era.09.7.

Abstract

Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / surgery
  • Chemotherapy, Adjuvant
  • Child
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Diphosphonates / administration & dosage
  • Docetaxel
  • Dogs
  • Drug Delivery Systems
  • Folic Acid Antagonists / administration & dosage
  • Humans
  • Immunologic Factors / administration & dosage
  • Neoadjuvant Therapy
  • Neoplasm Proteins / antagonists & inhibitors
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / surgery
  • Protein Kinase Inhibitors / administration & dosage
  • Radiopharmaceuticals / therapeutic use
  • Signal Transduction / drug effects
  • Survival Rate
  • Taxoids / administration & dosage
  • Xenograft Model Antitumor Assays
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • Diphosphonates
  • Folic Acid Antagonists
  • Immunologic Factors
  • Neoplasm Proteins
  • Protein Kinase Inhibitors
  • Radiopharmaceuticals
  • Taxoids
  • Deoxycytidine
  • Docetaxel
  • gemcitabine